

# Madeleine M Verhovsek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4800317/publications.pdf>

Version: 2024-02-01

44  
papers

885  
citations

686830

13  
h-index

476904

29  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1150  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic Review: $\alpha$ -Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2008, 149, 481.	2.0	234
2	Haptoglobin testing in hemolysis: Measurement and interpretation. <i>American Journal of Hematology</i> , 2014, 89, 443-447.	2.0	107
3	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. <i>Blood Advances</i> , 2019, 3, 3867-3897.	2.5	87
4	Unexpectedly low pulse oximetry measurements associated with variant hemoglobins: A systematic review. <i>American Journal of Hematology</i> , 2010, 85, 882-885.	2.0	72
5	Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2020, 95, 472-482.	2.0	47
6	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. <i>Haematologica</i> , 2019, 104, e51-e53.	1.7	46
7	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. <i>New England Journal of Medicine</i> , 2022, 386, 1432-1442.	13.9	42
8	Quality of anticoagulation and use of warfarin-interacting medications in long-term care: A chart review. <i>BMC Geriatrics</i> , 2008, 8, 13.	1.1	41
9	Laboratory testing for fibrinogen abnormalities. <i>American Journal of Hematology</i> , 2008, 83, 928-931.	2.0	39
10	How we diagnose and manage altered oxygen affinity hemoglobin variants. <i>American Journal of Hematology</i> , 2019, 94, 597-603.	2.0	38
11	Is HbA2 level a reliable diagnostic measurement for $\beta^0$ -thalassemia trait in people with iron deficiency?. <i>American Journal of Hematology</i> , 2012, 87, 114-116.	2.0	26
12	Ketamine administration for acute painful sickle cell crisis: A randomized controlled trial. <i>Academic Emergency Medicine</i> , 2022, 29, 150-158.	0.8	19
13	Comorbidities and complications in adults with pyruvate kinase deficiency. <i>European Journal of Haematology</i> , 2021, 106, 484-492.	1.1	17
14	Hb A <sub>2</sub> Hong Kong – A Novel $\beta$ -Globin Variant in a Chinese Family Masks the Diagnosis of $\beta^0$ -Thalassemia Trait. <i>Hemoglobin</i> , 2011, 35, 162-165.	0.4	12
15	Severe fetal and neonatal hemolytic anemia due to a 198bp deletion removing the complete $\beta^0$ -globin gene cluster. <i>Pediatric Blood and Cancer</i> , 2012, 59, 941-944.	0.8	11
16	Characterization of the severe phenotype of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2020, 95, E281.	2.0	8
17	Treating iron deficiency. <i>Cmaj</i> , 2017, 189, E409-E409.	0.9	5
18	Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: a randomized trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 266-268.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to risk-stratify patients for alloimmunisation risk. <i>Transfusion Medicine</i> , 2020, 30, 263-274.	0.5	3
20	Novel High Oxygen Affinity Hemoglobin Variant in a Patient with Polycythemia: Hb Kennisis [Î²85(F1)Pheâ†Leu (TTT>TTC); HBB: c.258T>G]. <i>Hemoglobin</i> , 2020, 44, 10-12.	0.4	2
21	The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea?. , 2019, 16, .		2
22	Emergency Department Quality of Care for Sickle Cell Disease in Ontario, Canada: A Population-Based Matched Cohort Study. <i>Blood</i> , 2020, 136, 38-39.	0.6	2
23	Radiologyâ€“pathology conference: neutrophilic fasciitis and panniculitis of the feet (Sweet's) Tj ETQq1 1 0.784314 rgBT /Overlock 1071	0.8	1
24	Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report. <i>African Health Sciences</i> , 2015, 14, 1069.	0.3	1
25	Hb Grifton [Î±87(F8)Hisâ†Pro; <i>HBA1</i>: C.263Aâ€%&gt;â€%C (or <i>HBA2</i>)] Causes Abnormal Pulse Oximetry Measurements. <i>Hemoglobin</i> , 2016, 40, 257-259.	0.4	1
26	A 19-year-old woman with sickle cell disease and pain. <i>Cmaj</i> , 2016, 188, 745-746.	0.9	1
27	Pharmacy hydroxyurea education materials for patients with sickle cell disease: An environmental scan and assessment of accuracy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28179.	0.8	1
28	Stuttering Priapism in a Patient with Sickle Cell Trait Treated with Automated Red Cell Exchange Transfusion. <i>Blood Advances</i> , 2021, 5, 5020-5022.	2.5	1
29	Variability In Hb A2 levels among Individuals with Beta-Thalassemia Trait: Is Iron Deficiency Associated with Abnormally Low Hb A2?. <i>Blood</i> , 2010, 116, 4281-4281.	0.6	1
30	Transition of Care Under One Roof at the McMaster Hemoglobinopathy Clinic. <i>Blood</i> , 2014, 124, 4851-4851.	0.6	1
31	Pilot Study of Online Learning Modules for Hemoglobinopathy Education in Canadian Hematology Training Programs. <i>Blood</i> , 2016, 128, 314-314.	0.6	1
32	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. <i>Blood</i> , 2018, 132, 4807-4807.	0.6	1
33	Use of Thromboprophylaxis for Central Venous Access Devices in Patients with Sickle Cell Disease: A Survey of Canadian Providers. <i>Blood</i> , 2021, 138, 4173-4173.	0.6	1
34	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. <i>Blood</i> , 2021, 138, 848-848.	0.6	1
35	A novel means of identifying hemoglobin Tacoma utilizing capillary electrophoresis with a hemoglobin A1c software platform. <i>Cogent Medicine</i> , 2021, 8, .	0.7	1
36	Pulse oximetry screening for critical congenital heart defects. <i>Lancet, The</i> , 2012, 380, 1305-1306.	6.3	0

#	ARTICLE	IF	CITATIONS
37	Microcytosis in patients with haemoglobin C trait: is it thalassaemia trait to blame?. British Journal of Haematology, 2020, 191, e129-e131.	1.2	0
38	Existing Warfarin Therapy in Long-Term Care Facilities Maybe Inadequate.. Blood, 2005, 106, 4160-4160.	0.6	0
39	Severe Fetal and Neonatal Anemia Due to Heterozygosity for a 198 Kb Deletion Removing the Entire $\beta$ -Globin Gene Cluster. Blood, 2010, 116, 5171-5171.	0.6	0
40	Hemoglobinopathy Education in Canadian Hematology Training Programs: How Much Are Residents Learning?. Blood, 2014, 124, 2168-2168.	0.6	0
41	Red Cell Antigen Genotyping Compared to Standard Serological Phenotyping in Sickle Cell Disease Patients in Canada: Potential for Reducing Alloimmunization. Blood, 2015, 126, 3404-3404.	0.6	0
42	Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. Blood, 2019, 134, 949-949.	0.6	0
43	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175.	0.6	0
44	Combined preoperative plasma exchange and red blood cell exchange transfusion in a renal transplant patient with protein S deficiency and hemoglobin SC disease. Transfusion and Apheresis Science, 2021, , 103345.	0.5	0